Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 154-157, 2015.
Article Dans Chinois | WPRIM | ID: wpr-476685

Résumé

Objective To investigate the effect of formoononetin on endostatin ( ES ) , vascular endothelial growth factor ( VEGF ) , matrix metalloproteinases 2(MMP-2), basic fibroblast growth factor (bFGF) in hydrothorax and serum, and tumor biomarkers of patients with elderly advanced lung cancer.Methods 67 cases elder with advanced lung cancer were selected and randomly divided into two groups.33 cases in control group were treated with conventional therapy of NP chemotherapy regimen, 34 cases in experiment group were combined with formononetin.The changes of ES, VEGF, MMP-2, bFGF, tumor marker levels in hydrothorax and serum and life quality evaluation were compared.ResuIts Compared with control group, the contents of ES, VEGF, MMP-2, bFGF in hydrothorax and serum of experiment group significantly decreased (P<0.05); the carcino embryonie antigen (CEA), neuron specific enolase (NSE), cytokeratin-19-fragments (CYFRA21-1), and carbohydrate antigen 125 (CA125) in serum of experiment group significantly decreased ( P<0.05 ); the life quality evaluation improved better of experiment group (χ2 =4.96, P<0.05 ). ConcIusion Formononetin has better clinical effect in treatment of elderly patients with advanced lung cancer patients.It could effectively improve the quality of life, reduce ES, VEGF, MMP-2, bFGF and other indicators in hydrothorax and serum, which has the vital significance to the clinical therapy.

SÉLECTION CITATIONS
Détails de la recherche